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Goals and Approach 
Investigating penicillin binding proteins in Borrelia burgdorferi: searching for 




Penicillin binding proteins (PBPs) are found in many 
bacteria and are characterized by their affinity for and 
binding of penicillin and other β-lactam antibiotics. 
Most bacteria have several PBPs, and these proteins 
can be membrane-bound or cytoplasmic. 
 
PBPs are involved in the final steps of peptidoglycan 
synthesis. Peptidoglycan is a major component of 
bacterial cell walls, so the action of PBPs is absolutely 
essential for the survival and proliferation of bacteria. 
If the action of PBPs is inhibited, the structure of the 
cell wall suffers and the cell often undergoes lysis.  
Penicillin Binding Proteins 
β-lactam antibiotics bind to the PBPs because of their 
structural resemblance to the building blocks of 
peptidoglycan. The binding of a β-lactam antibiotic to 
the PBP results in the formation of a covalent bond 
between the antibiotic and the catalytic serine residue 
at the active site. This binding results in permanent 
deactivation of the PBP. 
 
Figure 2. The action of the glycosyltransferase (GT) domain of 
PBPs in the construction of peptidoglycan component of 
bacterial cell walls. The GT domain polymerizes peptidyl lipid 
sugars from the membrane, creating a peptidyl sugar 
backbone. The backbone is passed to the transpeptidase (TP) 
domain, which cross-links the peptides to construct the 
peptidoglycan (Strynadka and Borman, 2007). 
Figure 1. Structures of Gram-positive and Gram-negative bacterial 
cell walls. Figure courtesy of Sigma-Aldrich. 
Borrelia burgdorferi and Lyme Disease 
Borrelia burgdorferi is a spirochete bacteria found in 
North America and Europe, and it is the primary cause 
of Lyme disease. It is a unique bacterial species 
because it is neither Gram-positive nor Gram-negative; 
instead, like other members of the phylum, it is a 
diderm (double membrane) species.  
 
B. burgdorferi is spread by ticks of the Ixodes genus—
specifically Ixodes scapularis in the Midwest and 
northeastern regions of the United States. Not 
surprisingly, Lyme disease is much more common in 
these regions than the rest of the country. 
Figure 3. The life cycle of the deer tick (Ixodes scapularis) divided 
into seasons. The tick has a two year life cycle and requires three 
blood meals during this time. If the tick picks up Borrelia burgdorferi 
during its first meal, it can pass the bacteria to a human in its 
second meal (Figure courtesy of Pearson Education).  
If the infection is caught early, Lyme disease is 
typically treated with oral administration of 
doxycycline (except in children under 8 years of age 
or pregnant/breastfeeding women; the alternative is 
usually amoxicillin or azithromycin). Doxycycline is 
used because of its effectiveness against B. 
burgdorferi along with other bacteria the tick may 
have been carrying. In late stage infections, patients 
may begin having cardiac, arthritic, and neurological 
symptoms and are treated with intravenous 
administration of the β-lactam antibiotic ceftriaxone.  
 
Despite treatment, some patients have lasting 
symptoms that persist for years after infection. 
Sometimes called Post-treatment Lyme Disease 
Syndrome, patients often suffer from fatigue, joint and 
muscle pain, and neurocognitive symptoms.   
 
The exact cause of the Post-Treatment Lyme Disease 
Syndrome is unknown. One theory is that the 
bacteria, when exposed to a stressor like an 
antibiotic, go into a dormant cyst state that allows 
them to survive treatment. After the stressor is 
removed, they return to the active spirochete form 
and the infection continues.  Another possibility is that 
the bacteria have become resistant to the antibiotic. 
Treatment failure could result from the Borrelia developing resistance 
to the drug.  This could occur due to a change in the base pairs 
within the 16S ribosomal subunit where DNA binds or within the 
penicillin binding protein sequences where ceftriaxone binds. By 
studying this region as well as the PBPs and their binding affinities to 
various β-lactam antibiotics, we can answer questions regarding 
treatment failure. 
PCR and Bioinformatics 
Donations of Ixodes scapularis, the primary vector, were acquired 
from various regions of Minnesota. A nested PCR assay was created 
to amplify the region of the B. burgdorferi genome known to interact 
with doxycycline and penicillin binding protein 3 predicted to interact 
with ceftriaxone. After gel electrophoresis, the products were sent for 
sequencing. Using DNA sequence validation through the BLAST 
database, we were then able to compare strains in MN for molecular 
modifications leading to any potential resistance.   
 Detection of PBPs 
BOCILLIN-FL (penicillin V conjugated to BODIPY-FL dye) is a 
fluorescent β-lactam used to identify PBPs and visualize them in 
living cells. In this experiment, B. burgdorferi cells were treated with 
BOCILLIN-FL and the cell membranes were isolated through 
ultracentrifugation. The resulting protein was then run on an SDS-
PAGE gel for quantification via Western blotting.  
PCR and Bioinformatics 
Detection of PBPs 
Due to several unexpected problems with the assay, numerous 
attempts with the Western blotting have resulted in blank blots. This 
is likely due to a lack of sufficient protein extracted in the form of cell 
membranes from the bacteria, so the signal is undetectable. 
However, dot blot analysis of pure lysate indicated binding of the 
Bocillin and responsiveness to the antibody, so measures are 
currently being taken to enrich for the cell membrane and get more 
protein for the SDS-PAGE analysis. 
PCR and Bioinformatics 
Detection of PBPs 
The first goal for future work is to get the assay working 
successfully, which likely is a matter of using more B. 
burgdorferi for the lysates in order to gain more protein for 
the Western blot. The second goal is to perform competition 
assays using various β-lactam antibiotics to ascertain the 
binding affinities of the antibiotics to the PBPs. 
Figure 5. Sample blot of a competition assay using BOCILLIN-FL. A 
culture of Escherichia coli was treated with varying concentrations of 
ceftriaxone followed by a fixed amount of BOCILLIN-FL. The bands 
show the binding of BOCILLIN-FL; darker bands indicate more binding 
by BOCILLIN-FL and less binding by the antibiotic (Kocaoglu and 
Carlson, 2015). 
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Materials and Methods 
Figure 4. Results of primary and nested PCR on a 2% agarose gel. (A) DNA extraction and 
PCR targeting the 16S ribosomal region and penicillin binding protein 3 of a lab culture of 
Borrelia burgdorferi. This was done to ensure the assay was working properly before testing 
the Ixodes scapularis for the presence of the bacteria. (B) DNA extraction and PCR targeting 
the 16S ribosomal tetracycline binding region of B. burgdorferi obtained from inside I. 
scapularis samples collected across Minnesota. Three of the six ticks showed a positive 
result, indicating the presence of B. burgdorferi.  
Introduction/Background 
A B 
In addition to the amplification of the 16S ribosomal region 
and waiting on the sequencing from the PCR, we are also 
searching for methods that allow us to culture the bacteria 
from the ticks in order to carry out future experiments testing 
for antibiotic resistance.  
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